Novel Bifunctional Conjugates Targeting PD-L1/PARP7 as Dual Immunotherapy for Potential Cancer Treatment

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer2005 · 792 citations
2. 2Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective2020 · 71 citations
3. 3Cancer immunotherapy comes of age2011 · 3,877 citations
4. 4PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression2017 · 976 citations
5. 5Design, Synthesis, and Biological Evaluation of Linear Aliphatic Amine-Linked Triaryl Derivatives as Potent Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction with Promising Antitumor Effects In Vivo2020 · 45 citations